Crinecerfont in a First Clinical Application of a CRH Antagonist: Further Potential Uses Are Still an Open Chapter!

Affiliations

¹ University Research Institute of Maternal and Child Health and Precision Medicine and UNESCO Chair on Adolescent Health Care, National and Kapodistrian University of Athens, Athens 11527, Greece.

Editorial

George P Chrousos. J Clin Endocrinol Metab. 2024.

. 2024 Mar 15;109(4):e1365-e1366.

doi: 10.1210/clinem/dgad513.

¹ University Research Institute of Maternal and Child Health and Precision Medicine and UNESCO Chair on Adolescent Health Care, National and Kapodistrian University of Athens, Athens 11527, Greece.

No abstract available

Keywords: 21-hydroxylase; ACTH; CAH; CRH; CRH receptor; antalarmin; glucocorticoids; stresscopin; tildacerfont; urocortin.

Comment on

Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia.
Newfield RS, Sarafoglou K, Fechner PY, Nokoff NJ, Auchus RJ, Vogiatzi MG, Jeha GS, Giri N, Roberts E, Sturgeon J, Chan JL, Farber RH. Newfield RS, et al. J Clin Endocrinol Metab. 2023 Oct 18;108(11):2871-2878. doi: 10.1210/clinem/dgad270. J Clin Endocrinol Metab. 2023. PMID: 37216921 Free PMC article.